LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

Search

Akebia Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

3.57 0.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.53

Max

3.67

Schlüsselkennzahlen

By Trading Economics

Einkommen

29M

6.1M

Verkäufe

11M

57M

EPS

0.025

Gewinnspanne

10.66

Angestellte

181

EBITDA

20M

14M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+89.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

395M

1B

Vorheriger Eröffnungskurs

2.72

Vorheriger Schlusskurs

3.57

Nachrichtenstimmung

By Acuity

20%

80%

33 / 381 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Juni 2025, 22:33 UTC

Akquisitionen, Fusionen, Übernahmen

KKR to Acquire Australian Power Provider Zenith Energy

16. Juni 2025, 21:55 UTC

Wichtige Markttreiber

Geospace Technologies Shares Up on Petrobras Pact

16. Juni 2025, 17:04 UTC

Wichtige Markttreiber

Roku Shares Climb on Advertising Deal with Amazon

16. Juni 2025, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Juni 2025, 23:51 UTC

Market Talk

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16. Juni 2025, 23:41 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16. Juni 2025, 23:10 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16. Juni 2025, 23:02 UTC

Market Talk

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16. Juni 2025, 22:32 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16. Juni 2025, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16. Juni 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16. Juni 2025, 21:56 UTC

Ergebnisse

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16. Juni 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Juni 2025, 20:49 UTC

Market Talk

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16. Juni 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16. Juni 2025, 20:13 UTC

Market Talk

Natural Gas Gains on Warmer Outlook -- Market Talk

16. Juni 2025, 19:58 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16. Juni 2025, 19:13 UTC

Market Talk

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16. Juni 2025, 19:09 UTC

Market Talk

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16. Juni 2025, 18:43 UTC

Market Talk

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16. Juni 2025, 18:36 UTC

Market Talk

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16. Juni 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Juni 2025, 18:29 UTC

Market Talk

Shopify Appears More Resilient Than Feared -- Market Talk

16. Juni 2025, 18:22 UTC

Market Talk

Citi Forecasts Downturn in Gold Futures -- Market Talk

16. Juni 2025, 16:42 UTC

Market Talk

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16. Juni 2025, 16:37 UTC

Market Talk

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

89.61% Vorteil

12-Monats-Prognose

Durchschnitt 6.75 USD  89.61%

Hoch 8 USD

Tief 6 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

33 / 381 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.